On the filings, DexCom (DXCM) is the stronger stock right now — higher on our blended fundamentals-plus-verdict read, and we currently rate it BUY.
High-quality CGM compounder: 15%+ revenue and 45%+ earnings growth at a reasonable 34x, but a 2028 Medicare reimbursement cut caps conviction.
Best-in-class Omnipod growth story trading at its multiple — own it, but the price already pays for the execution.
| Metric | DXCM | PODD |
|---|---|---|
| Fundamentals score | 84 | 69 |
| Revenue growth (YoY) | +15.6% | +30.7% |
| Net income growth (YoY) | +45.1% | -40.9% |
| Net margin | 17.9% | 9.1% |
| Return on equity | 30.5% | 16.3% |
| ROIC (est.) | 26.2% | 12.9% |
| Liabilities / Equity | 1.31 | 1.11 |
| Piotroski F-score | 8 / 9 | 5 / 9 |
Bold green = the stronger figure. All rows derive from SEC XBRL filings — no market-price data on this page.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 3:04 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 25, 2026, 9:43 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.